Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis

Cancer Research

Volumn 71, Issue 13, 2011, Pages 4506-4517

  Lee, Ae Sin ^a   Kim, Duk Hoon ^a   Lee, Jung Eun ^a   Jung, Yu Jin ^a   Kang, Kyung Pyo ^a   Lee, Sik ^a   Park, Sung Kwang ^a   Kwak, Jae Yong ^a   Lee, Sang Yong ^a   Lim, Suk Tae ^a   Sung, Mi Jung ^b   Yoon, Suk Ran ^c   Kim, Won ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Korea Food Research Institute   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; ERYTHROPOIETIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD11B; CELL LINE, TUMOR; ERYTHROPOIETIN; FEMALE; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ONCOGENE PROTEIN V-AKT; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 79959863771     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3787     Document Type: Article

References (43)

1. Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A, et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 2005;130:877-8.
2. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104:2073-80. (Pubitemid 39297859)
3. Siren AL, Ehrenreich H. Erythropoietin - a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251:179-84. (Pubitemid 32963495)
4. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74. (Pubitemid 32538196)
5. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14. (Pubitemid 32816195)
6. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60. (Pubitemid 37324251)
7. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32. (Pubitemid 46596751)
8. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
9. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23:1797-805. (Pubitemid 35355929)
10. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W, Haroon ZA. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005;18:421-30. (Pubitemid 40395362)
11. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008;10:932-9.
12. Dachs GU, Chaplin DJ. Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol 1998;8:208-16. (Pubitemid 28323479)
13. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-9.
14. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36. (Pubitemid 29181195)
15. Dadras SS, Detmar M. Angiogenesis and lymphangiogenesis of skin cancers. Hematol Oncol Clin North Am 2004;18:1059-70, viii.
16. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005;201:1089-99. (Pubitemid 40524677)
17. Ji RC. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol 2009;24:377-84.
18. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006;66:10365-76.
19. Van Den Eynden GG, Vandenberghe MK, van Dam PJ, Colpaert CG, van Dam P, Dirix LY, et al. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin Cancer Res 2007;13:5391-7. (Pubitemid 47510365)
20. + macrophages in advanced ovarian cancer. Cancer Res 2008;68:1100-9.
21. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46. (Pubitemid 46009952)
22. Hsieh MJ, Chen KS, Chiou HL, Hsieh YS. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. Eur J Cell Biol 2010;89:598-606.
23. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002;94:819-25. (Pubitemid 34705053)
24. + macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood 2009;113:5650-9.
25. Kim W, Moon SO, Lee S, Sung MJ, Kim SH, Park SK. Adrenomedullin reduces VEGF-induced endothelial adhesion molecules and adhesiveness through a phosphatidylinositol 30-kinase pathway. Arterioscler Thromb Vasc Biol 2003;23:1377-83. (Pubitemid 36994525)
26. Sung MJ, Kim W, Ahn SY, Cho CH, Koh GY, Moon SO, et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression. Circ Res 2005;97:880-90. (Pubitemid 41552673)
27. Bruyere F, Melen-Lamalle L, Blacher S, Roland G, Thiry M, Moons L, et al. Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods 2008;5:431-7. (Pubitemid 351619102)
28. Woditschka S, Haag JD, Mau B, Lubet RA, Gould MN. Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. Breast Cancer Res 2008;10:R18.
29. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest 2005;115:2316-9. (Pubitemid 41266190)
30. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56. (Pubitemid 34988382)
31. Da MX, Wu Z, Tian HW. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008;39:365-72.
32. Miyahara M, Tanuma J, Sugihara K, Semba I. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer 2007;110:1287-94. (Pubitemid 47435600)
33. Saaristo A, Veikkola T, Enholm B, Hytonen M, Arola J, Pajusola K, et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J 2002;16:1041-9. (Pubitemid 34753510)
34. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548-53.
35. Chang LK, Garcia-Cardena G, Farnebo F, Fannon M, Chen EJ, Butterfield C, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A 2004;101:11658-63. (Pubitemid 39095352)
36. Morisada T, Oike Y, Yamada Y, Urano T, Akao M, Kubota Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005;105:4649-56. (Pubitemid 40807284)
37. Dellinger M, Hunter R, Bernas M, Gale N, Yancopoulos G, Erickson R, et al. Defective remodeling and maturation of the lymphatic vasculature in angiopoietin-2 deficient mice. Dev Biol 2008;319:309-20.
38. Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, Galter D, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6:333-45. (Pubitemid 39361435)
39. Janmaat ML, Heerkens JL, de Bruin AM, Klous A, de Waard V, de Vries CJ. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010;115:1453-60.
40. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, et al. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 2010;8:615-26.
41. Fu P, Jiang X, Arcasoy MO. Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun 2009;379:696-701.
42. Haribalaganesh R, Sheikpranbabu S, Banumathi E, Gurunathan S. Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway. Exp Eye Res 2010;90:726-33.
43. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009;1796:11-8.